279 related articles for article (PubMed ID: 15536148)
1. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
Beelen DW; Ottinger HD; Ferencik S; Elmaagacli AH; Peceny R; Trenschel R; Grosse-Wilde H
Blood; 2005 Mar; 105(6):2594-600. PubMed ID: 15536148
[TBL] [Abstract][Full Text] [Related]
2. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.
Verheyden S; Schots R; Duquet W; Demanet C
Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
4. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.
Giebel S; Locatelli F; Lamparelli T; Velardi A; Davies S; Frumento G; Maccario R; Bonetti F; Wojnar J; Martinetti M; Frassoni F; Giorgiani G; Bacigalupo A; Holowiecki J
Blood; 2003 Aug; 102(3):814-9. PubMed ID: 12689936
[TBL] [Abstract][Full Text] [Related]
5. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
7. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
8. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.
Willemze R; Rodrigues CA; Labopin M; Sanz G; Michel G; Socié G; Rio B; Sirvent A; Renaud M; Madero L; Mohty M; Ferra C; Garnier F; Loiseau P; Garcia J; Lecchi L; Kögler G; Beguin Y; Navarrete C; Devos T; Ionescu I; Boudjedir K; Herr AL; Gluckman E; Rocha V;
Leukemia; 2009 Mar; 23(3):492-500. PubMed ID: 19151783
[TBL] [Abstract][Full Text] [Related]
9. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
Wang H; He Y; Zhai WJ; Wang M; Zhou Z; Zhao YX; Feng SZ; Han MZ
Swiss Med Wkly; 2013; 143():w13717. PubMed ID: 23299929
[TBL] [Abstract][Full Text] [Related]
10. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
[TBL] [Abstract][Full Text] [Related]
11. Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation.
Sivula J; Volin L; Porkka K; Vettenranta K; Itälä M; Partanen J; Turpeinen H
Transpl Immunol; 2007 Jul; 18(1):62-6. PubMed ID: 17584604
[TBL] [Abstract][Full Text] [Related]
12. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.
Ruggeri L; Mancusi A; Capanni M; Urbani E; Carotti A; Aloisi T; Stern M; Pende D; Perruccio K; Burchielli E; Topini F; Bianchi E; Aversa F; Martelli MF; Velardi A
Blood; 2007 Jul; 110(1):433-40. PubMed ID: 17371948
[TBL] [Abstract][Full Text] [Related]
13. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation.
Schaffer M; Malmberg KJ; Ringdén O; Ljunggren HG; Remberger M
Transplantation; 2004 Oct; 78(7):1081-5. PubMed ID: 15480179
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.
Davies SM; Ruggieri L; DeFor T; Wagner JE; Weisdorf DJ; Miller JS; Velardi A; Blazar BR
Blood; 2002 Nov; 100(10):3825-7. PubMed ID: 12393440
[TBL] [Abstract][Full Text] [Related]
15. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
16. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
17. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
[TBL] [Abstract][Full Text] [Related]
18. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
[TBL] [Abstract][Full Text] [Related]
19. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
20. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
